Lakeshore biopharma regains compliance with nasdaq minimum bid price requirement

Gaithersburg, md., oct. 29, 2024 /prnewswire/ -- lakeshore biopharma co., ltd (nasdaq: lsb) ("lakeshore biopharma" or the "company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a written notice (the "compliance notice") from the listing qualifications department of the nasdaq stock market llc ("nasdaq") dated october 21, 2024, informing the company that it has regained compliance with the minimum bid price requirement set forth under the nasdaq listing rule 5550(a)(2) (the "minimum bid price requirement").
LSB Ratings Summary
LSB Quant Ranking